An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

Inclusion Criteria Concurrent Medication: Allowed: * Standard therapy for infections. * Acyclovir. * Ganciclovir. * Allowed only with permission of Wyeth-Ayerst medical monitor: * Zidovudine (AZT). * Immunomodulators. * Specific therapy for malignancies (including Kaposi's sarcoma). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Evidence of severe liver dysfunction (serum albumin \< 3 g/dl, SGOT or SGPT \> 5 x upper limit of normal, prothrombin time \> 15 seconds), or gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular system abnormalities or psychiatric disorder other than abnormalities secondary to AIDS or AIDS related complex (ARC). * Evidence of AIDS-related central nervous system involvement. * Disseminated Kaposi's sarcoma. Concurrent Medication: Excluded without permission of Wyeth-Ayerst medical monitor: * Zidovudine (AZT). * Immunomodulators. * Specific therapy for malignancies (including Kaposi's sarcoma). Patients with the following are excluded: * Evidence of major system abnormalities other than abnormalities secondary to AIDS or AIDS related complex. * Concomitant conditions as specified in Patient Exclusion Co-existing Conditions. * Unlikely or unable to comply with the requirements of the protocol. Prior Medication: Excluded within 4 weeks of study entry: * Systemic antiviral agents. * Immunosuppressive agents. * Immune stimulators such as BCG vaccine, isoprinosine, or other immunomodulators. Patients must: * Have a diagnosis of AIDS or AIDS related complex (ARC). * Demonstrate intolerance or refusal to take zidovudine (AZT). * Provide written informed consent.